A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis

Jin Endo; Motoaki Sano; Yasuhiro Izumiya; Kenichi Tsujita; Kazufumi Nakamura; Nobuhiro Tahara; Koichiro Kuwahara; Takayuki Inomata; Mitsuharu Ueda; Yoshiki Sekijima; Yukio Ando; Hiroyuki Tsutsui; Mitsuaki Isobe; Keiichi Fukuda

doi:10.1253/circj.CJ-19-0811

A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis

Jin Endo, Motoaki Sano, Yasuhiro Izumiya, Kenichi Tsujita, Kazufumi Nakamura, Nobuhiro Tahara, Koichiro Kuwahara, Takayuki Inomata, Mitsuharu Ueda, Yoshiki Sekijima, Yukio Ando, Hiroyuki Tsutsui, Mitsuaki Isobe, Keiichi Fukuda

Department of Internal Medicine (Cardiology)

Research output: Contribution to journal › Review article › peer-review

15 Citations (Scopus)

Abstract

Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel®, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.

Original language	English
Pages (from-to)	15-17
Number of pages	3
Journal	Circulation Journal
Volume	84
Issue number	1
DOIs	https://doi.org/10.1253/circj.CJ-19-0811
Publication status	Published - 2019

Keywords

ATTR cardiac amyloidosis
Amyloid
Japanese Circulation Society
Japanese Ministry of Health, Labour and Welfare (JMHLW)
Tafamidis

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1253/circj.CJ-19-0811

Cite this

@article{52124a8ac3584b60a8db6e9c98637a95,

title = "A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis",

abstract = "Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel{\textregistered}, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.",

keywords = "ATTR cardiac amyloidosis, Amyloid, Japanese Circulation Society, Japanese Ministry of Health, Labour and Welfare (JMHLW), Tafamidis",

author = "Jin Endo and Motoaki Sano and Yasuhiro Izumiya and Kenichi Tsujita and Kazufumi Nakamura and Nobuhiro Tahara and Koichiro Kuwahara and Takayuki Inomata and Mitsuharu Ueda and Yoshiki Sekijima and Yukio Ando and Hiroyuki Tsutsui and Mitsuaki Isobe and Keiichi Fukuda",

year = "2019",

doi = "10.1253/circj.CJ-19-0811",

language = "English",

volume = "84",

pages = "15--17",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "1",

}

TY - JOUR

T1 - A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis

AU - Endo, Jin

AU - Sano, Motoaki

AU - Izumiya, Yasuhiro

AU - Tsujita, Kenichi

AU - Nakamura, Kazufumi

AU - Tahara, Nobuhiro

AU - Kuwahara, Koichiro

AU - Inomata, Takayuki

AU - Ueda, Mitsuharu

AU - Sekijima, Yoshiki

AU - Ando, Yukio

AU - Tsutsui, Hiroyuki

AU - Isobe, Mitsuaki

AU - Fukuda, Keiichi

PY - 2019

Y1 - 2019

N2 - Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel®, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.

AB - Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel®, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.

KW - ATTR cardiac amyloidosis

KW - Amyloid

KW - Japanese Circulation Society

KW - Japanese Ministry of Health, Labour and Welfare (JMHLW)

KW - Tafamidis

UR - http://www.scopus.com/inward/record.url?scp=85077222802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077222802&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-19-0811

DO - 10.1253/circj.CJ-19-0811

M3 - Review article

C2 - 31735731

AN - SCOPUS:85077222802

SN - 1346-9843

VL - 84

SP - 15

EP - 17

JO - Circulation Journal

JF - Circulation Journal

IS - 1

ER -

A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this